FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313532482> ?p ?o ?g. }

• W4313532482 abstract "<h3>Background</h3> Identification of prognostic and predictive biomarkers in lupus nephritis (LN) is an area of intense study and interest. Non-invasive laboratory markers that associate with the likelihood of responding to therapy and/or assess clinical response in patients with active LN remains an unmet need. The Lupus Risk Index is a score that associates with the risk of developing SLE.¹ It is lowest in Caucasian females and increases in populations with increased risk of developing SLE (African American, Sister9s of patients with SLE), and is highest in SLE. Its components (IgM and IgG anti-DNA antibodies and C1q) are each associated with renal disease (or protection from renal disease). LRI <h3>Objective</h3> To assess the LRI as a LN biomarker that predicts a clinical response to induction therapy, or whose early changes may precede a clinical response, or that associates with a clinical therapeutic response. <h3>Methods</h3> The LRI was determined on retrospective specimens collected from two LN clinical trials sponsored by the Immune Tolerance Network (ITN): CALIBRATE (n=43) and ACCESS (n=134) as well as healthy controls (n=70). Both trials enrolled subjects with active proliferative LN (Class III, IV, ± Class V). All subjects participating in CALIBRATE received rituximab (coupled with cyclophosphamide) and half received open-label belimumab through week 48 of the study. In ACCESS, all participants received the Euro-lupus cyclophosphamide protocol and subjects were randomized to receive either placebo or abatacept infusions. Sera obtained at weeks 0, 12, 24, and 48/52 (CALIBRATE/ACCESS) were studied. Levels of IgG αDNA, IgM αDNA and C1q were determined by ELISA. Response at 24 weeks was defined using the ITN’s definitions of renal response. This is a categorical assessment; a Complete Response (CR) requires a Urine protein:creatinine ratio (UPCR) ≤0.5 and creatinine normal or no greater than 125% of baseline, and a prednisone (or equivalent) dose ≤10 mg/d. 2), Partial Response (PR): UPCR ≥50% reduction from baseline plus identical creatinine and steroid criteria as CR, or 3) Non-response (NR) all others. <h3>Results</h3> Baseline LRI determined from ACCESS and CALIBRATE samples were both significantly higher than normal controls. Baseline LRI from CALIBRATE which recruited non-naïve disease LN patients, i.e., patients who were resistant to current therapy, or had a repeat LN episodes was significantly greater than those from ACCESS which allowed subjects with new onset lupus nephritis (Figure 1A). Neither the LRI at baseline nor the change of the LRI from baseline to week 12 predicted a subsequent renal response at 24 weeks (figure 2A and 2B). Moreover, the LRI at week 24 did not associate with a renal response at that timepoint (figure 2C). These results were confirmed when samples from ACCESS and CALIBRATE were assessed separately, or if only subjects receiving the active comparator (abatacept in ACCESS or belimumab in CALIBRATE) were examined. <h3>Conclusions</h3> The LRI, a measure associating with the risk of developing SLE, is not a predictive or prognostic biomarker in patients with active LN. <h3>Reference</h3> Bhattacharya J, Pappas K, Toz B, Aranow C, Mackay M, Gregersen PK, Doumbo O, Traore AK, Lesser ML, McMahon M, Utset T, Silverman E, Levy D, McCune WJ, Jolly M, Wallace D, Weisman M, Romero-Diaz J, Diamond B. Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus. <i>Mol Med</i> 2018 Jun 1;<b>24</b>(1):24. doi: 10.1186/s10020-018-0019-4. PMID: 30134810; PMCID: PMC6016868. <h3>Acknowledgements</h3> Immune Tolerance Network; Autoimmunity Centers of Excellence--NIAID, NIH" @default.
• W4313532482 created "2023-01-06" @default.
• W4313532482 creator A5015927371 @default.
• W4313532482 creator A5033178772 @default.
• W4313532482 creator A5073416718 @default.
• W4313532482 creator A5081646221 @default.
• W4313532482 creator A5089808423 @default.
• W4313532482 date "2022-12-01" @default.
• W4313532482 modified "2023-09-24" @default.
• W4313532482 title "301 The Lupus Risk Index (LRI) as a biomarker in patients with lupus nephritis" @default.
• W4313532482 doi "https://doi.org/10.1136/lupus-2022-lupus21century.12" @default.
• W4313532482 hasPublicationYear "2022" @default.
• W4313532482 type Work @default.
• W4313532482 citedByCount "0" @default.
• W4313532482 crossrefType "proceedings-article" @default.
• W4313532482 hasAuthorship W4313532482A5015927371 @default.
• W4313532482 hasAuthorship W4313532482A5033178772 @default.
• W4313532482 hasAuthorship W4313532482A5073416718 @default.
• W4313532482 hasAuthorship W4313532482A5081646221 @default.
• W4313532482 hasAuthorship W4313532482A5089808423 @default.
• W4313532482 hasBestOaLocation W43135324821 @default.
• W4313532482 hasConcept C126322002 @default.
• W4313532482 hasConcept C143998085 @default.
• W4313532482 hasConcept C159654299 @default.
• W4313532482 hasConcept C170286685 @default.
• W4313532482 hasConcept C185592680 @default.
• W4313532482 hasConcept C203014093 @default.
• W4313532482 hasConcept C2776694085 @default.
• W4313532482 hasConcept C2776755627 @default.
• W4313532482 hasConcept C2776912625 @default.
• W4313532482 hasConcept C2778453870 @default.
• W4313532482 hasConcept C2779134260 @default.
• W4313532482 hasConcept C2779605438 @default.
• W4313532482 hasConcept C2779912601 @default.
• W4313532482 hasConcept C2780653079 @default.
• W4313532482 hasConcept C2781197716 @default.
• W4313532482 hasConcept C2781205201 @default.
• W4313532482 hasConcept C535046627 @default.
• W4313532482 hasConcept C55493867 @default.
• W4313532482 hasConcept C71924100 @default.
• W4313532482 hasConceptScore W4313532482C126322002 @default.
• W4313532482 hasConceptScore W4313532482C143998085 @default.
• W4313532482 hasConceptScore W4313532482C159654299 @default.
• W4313532482 hasConceptScore W4313532482C170286685 @default.
• W4313532482 hasConceptScore W4313532482C185592680 @default.
• W4313532482 hasConceptScore W4313532482C203014093 @default.
• W4313532482 hasConceptScore W4313532482C2776694085 @default.
• W4313532482 hasConceptScore W4313532482C2776755627 @default.
• W4313532482 hasConceptScore W4313532482C2776912625 @default.
• W4313532482 hasConceptScore W4313532482C2778453870 @default.
• W4313532482 hasConceptScore W4313532482C2779134260 @default.
• W4313532482 hasConceptScore W4313532482C2779605438 @default.
• W4313532482 hasConceptScore W4313532482C2779912601 @default.
• W4313532482 hasConceptScore W4313532482C2780653079 @default.
• W4313532482 hasConceptScore W4313532482C2781197716 @default.
• W4313532482 hasConceptScore W4313532482C2781205201 @default.
• W4313532482 hasConceptScore W4313532482C535046627 @default.
• W4313532482 hasConceptScore W4313532482C55493867 @default.
• W4313532482 hasConceptScore W4313532482C71924100 @default.
• W4313532482 hasLocation W43135324821 @default.
• W4313532482 hasLocation W43135324822 @default.
• W4313532482 hasOpenAccess W4313532482 @default.
• W4313532482 hasPrimaryLocation W43135324821 @default.
• W4313532482 hasRelatedWork W2024423534 @default.
• W4313532482 hasRelatedWork W2034523904 @default.
• W4313532482 hasRelatedWork W2075960462 @default.
• W4313532482 hasRelatedWork W2174957077 @default.
• W4313532482 hasRelatedWork W2609958319 @default.
• W4313532482 hasRelatedWork W2782438068 @default.
• W4313532482 hasRelatedWork W2936915952 @default.
• W4313532482 hasRelatedWork W3151570599 @default.
• W4313532482 hasRelatedWork W4229034713 @default.
• W4313532482 hasRelatedWork W4288453585 @default.
• W4313532482 isParatext "false" @default.
• W4313532482 isRetracted "false" @default.
• W4313532482 workType "article" @default.